Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).

Alrashed, Fatema; Abdullah, Israa; Alfadhli, Ahmad; Shehab, Mohammad

Alrashed, Fatema; Abdullah, Israa; Alfadhli, Ahmad; Shehab, Mohammad.

Afiliación

Alrashed F; Department of Pharmacy Practice, College of Pharmacy, Kuwait University, Kuwait City, Kuwait.
Abdullah I; Department of Internal Medicine, Mubarak Al-Kabeer University Hospital, Jabriya, Kuwait.
Alfadhli A; Department of Internal Medicine, Mubarak Al-Kabeer University Hospital, Jabriya, Kuwait.
Shehab M; Department of Pharmacy Practice, College of Pharmacy, Kuwait University, Kuwait City, Kuwait.

Front Pharmacol ; 14: 1243080, 2023.

Article en En | MEDLINE | ID: mdl-37876726

Palabras clave

biologics; endoscopic; hospitalization; inflammatory bowel disease; remission; steroids; surgery

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Kuwait Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google